<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00988260</url>
  </required_header>
  <id_info>
    <org_study_id>P05969</org_study_id>
    <nct_id>NCT00988260</nct_id>
  </id_info>
  <brief_title>Japanese Bridging Trial of Org 37462 (Study P05969)(COMPLETED)</brief_title>
  <official_title>A Phase II Bridging Trial of Org 37462</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find the optimal dose of Org 37462 for Japanese females&#xD;
      undergoing controlled ovarian stimulation for in vitro fertilization intracytoplasmic sperm&#xD;
      injection (IVF-ICSI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 3, 2003</start_date>
  <completion_date type="Actual">April 12, 2004</completion_date>
  <primary_completion_date type="Actual">April 12, 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Luteinizing Hormone (LH) rise</measure>
    <time_frame>During treatment (1-14 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intrauterine vital pregnancy rate</measure>
    <time_frame>5-6 weeks after embryo transfer (ET)</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>Controlled Ovarian Stimulation</condition>
  <arm_group>
    <arm_group_label>Ganirelix 0.125 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ganirelix 0.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ganirelix 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganirelix</intervention_name>
    <description>Ganirelix 0.125 mg subcutaneous daily (SC OD) for up to 14 days</description>
    <arm_group_label>Ganirelix 0.125 mg</arm_group_label>
    <other_name>Org 37462</other_name>
    <other_name>SCH 900761</other_name>
    <other_name>Orgalutran</other_name>
    <other_name>Ganirelix Acetate</other_name>
    <other_name>Ganirest</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganirelix</intervention_name>
    <description>Ganirelix 0.25 mg subcutaneous daily (SC OD) for up to 14 days</description>
    <arm_group_label>Ganirelix 0.25 mg</arm_group_label>
    <other_name>Org 37462</other_name>
    <other_name>SCH 900761</other_name>
    <other_name>Orgalutran</other_name>
    <other_name>Ganirelix Acetate</other_name>
    <other_name>Ganirest</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganirelix</intervention_name>
    <description>Ganirelix 0.5 mg subcutaneous daily (SC OD) for up to 14 days</description>
    <arm_group_label>Ganirelix 0.5 mg</arm_group_label>
    <other_name>Org 37462</other_name>
    <other_name>SCH 900761</other_name>
    <other_name>Orgalutran</other_name>
    <other_name>Ganirelix Acetate</other_name>
    <other_name>Ganirest</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Japanese females of infertile married couples with an indication for COH and IVF with&#xD;
             or without ICSI.&#xD;
&#xD;
          -  At least 20 but not older than 39 years of age at the time of screening.&#xD;
&#xD;
          -  A body mass index (BMI) between 18 and 29.&#xD;
&#xD;
          -  Normal menstrual cycle with a range of 24-35 days and an intra-individual variation of&#xD;
             plus or minus 3 days (but never outside the 24-35 days range).&#xD;
&#xD;
          -  Infertile couple that is willing to give written informed consent.&#xD;
&#xD;
          -  Determination of inclusion criteria&#xD;
&#xD;
               -  is determined in view of the planned therapeutic indication.&#xD;
&#xD;
               -  is determined based on ethical considerations for the subjects (not younger than&#xD;
                  20) and also in view of the planned therapeutic indication (not older than 39)&#xD;
&#xD;
               -  is determined to avoid bias on the effects of Org 37462 by emaciation and&#xD;
                  obesity.&#xD;
&#xD;
               -  is determined to avoid the influences of endogenous hormones considering the&#xD;
                  purpose of this trial to select the minimal effective dose of Org 37462.&#xD;
&#xD;
               -  is determined from the ethical consideration of the subjects.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of/or current endocrine abnormality such as polycystic ovary syndrome (PCOS)&#xD;
             or polycystic ovaries according to USS, (treated) hyperprolactinemia or evidence of&#xD;
             ovarian dysfunction.&#xD;
&#xD;
          -  History of non- or low- ovarian response to FSH/hMG treatment.&#xD;
&#xD;
          -  Abnormal cervical smear according to the Papanicolaou (&gt;= class III) or Bethesda (&gt;=&#xD;
             CIN 1) scale.&#xD;
&#xD;
          -  History of/or current Type I hypersensitivity (urticaria, eczema, hay fever, asthma),&#xD;
             meaning that the subject is using prescribed medication on a regular basis or that the&#xD;
             subjects history is prohibitive for Org 37462 treatment according to the clinical&#xD;
             opinion of the sub-investigator.&#xD;
&#xD;
          -  Any hormone value outside the reference range during the early follicular phase as&#xD;
             measured by the central laboratory (Japan) [FSH, LH, E2, P, androstenedione (AD),&#xD;
             dehydroepiandrosterone sulphate (DHEAS), testosterone (T), thyroid stimulating hormone&#xD;
             (TSH) and prolactin].&#xD;
&#xD;
          -  Any clinically significant abnormal laboratory value of the central laboratory (Japan)&#xD;
             (routine hematology, blood biochemistry).&#xD;
&#xD;
          -  Any ovarian and/or abdominal abnormality that would interfere with adequate ultrasound&#xD;
             investigation of both ovaries, thus excluding subjects with only one ovary.&#xD;
&#xD;
          -  Contra-indications for the use of gonadotropins i.e.,&#xD;
&#xD;
               -  tumors of ovary, breast, uterus, pituitary or hypothalamus.&#xD;
&#xD;
               -  pregnancy or lactation.&#xD;
&#xD;
               -  undiagnosed vaginal bleeding.&#xD;
&#xD;
               -  hypersensitivity to any of the substances in recFSH (FSH, sucrose, sodium&#xD;
                  citrate, polysorbate 20 and sodium chloride, L-methionine).&#xD;
&#xD;
               -  ovarian cysts or enlarged ovaries not related to PCOS.&#xD;
&#xD;
               -  malformation of the sexual organs incompatible with pregnancy.&#xD;
&#xD;
               -  fibroid tumors of the uterus incompatible with pregnancy.&#xD;
&#xD;
          -  Use of hormonal preparations within 1 month prior to screening.&#xD;
&#xD;
          -  Hypertension (systolic blood pressure &gt;150 mm Hg and/or diastolic blood pressure &gt;90&#xD;
             mm Hg) or treated hypertension.&#xD;
&#xD;
          -  Epilepsia, diabetes, cardiovascular, gastro-intestinal, hepatic, renal, pulmonary, or&#xD;
             abdominal disease.&#xD;
&#xD;
          -  Administration of investigational drugs within 3 months prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>October 1, 2009</study_first_submitted>
  <study_first_submitted_qc>October 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2009</study_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganirelix</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

